Hutchison China MediTech Ltd. (HCM)

33.26
0.24 0.72
NASDAQ : Health Technology
Prev Close 33.50
Open 33.60
Day Low/High 32.80 / 33.71
52 Wk Low/High 18.30 / 42.25
Volume 19.98K
Avg Volume 89.20K
Exchange NASDAQ
Shares Outstanding 121.30M
Market Cap 4.31B
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Chi-Med Completes Enrollment Of 527 Patients In Pivotal Phase III FALUCA Trial With Fruquintinib In Lung Cancer

Chi-Med Completes Enrollment Of 527 Patients In Pivotal Phase III FALUCA Trial With Fruquintinib In Lung Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has completed patient enrollment of FALUCA, its Phase III pivotal trial of f ruquintinib in a dvanced, third-line, non-small cell lu ng ca ncer...

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib.

Chi-Med Initiates FRUTIGA, A Phase III Trial Of Fruquintinib In Second-Line Gastric Cancer

Chi-Med Initiates FRUTIGA, A Phase III Trial Of Fruquintinib In Second-Line Gastric Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) has initiated FRUTIGA, a pivotal Phase III clinical trial of fru quintinib in combination with paclitaxel ( T axol ®) for the treatment i n advanced...

Chi-Med Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million On The Nasdaq Global Select Market

Chi-Med Announces The Closing Of U.S. Public Offering Of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million On The Nasdaq Global Select Market

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously announced...

Chi-Med Announces The Full Exercise Of Underwriters' Over-allotment Option

Chi-Med Announces The Full Exercise Of Underwriters' Over-allotment Option

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hutchison China MediTech...

Chi-Med Announces Pricing Of U.S. Public Offering Of ADSs Raising US$262 Million On Nasdaq Global Select Market

Chi-Med Announces Pricing Of U.S. Public Offering Of ADSs Raising US$262 Million On Nasdaq Global Select Market

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017.

Chi-Med Announces Proposed Offering Of ADSs

Chi-Med Announces Proposed Offering Of ADSs

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.

Chi-Med And AstraZeneca's Savolitinib Shows Encouraging Clinical Activity In Second-Line EGFR Mutation-Positive Lung Cancer With MET-Amplification

Chi-Med And AstraZeneca's Savolitinib Shows Encouraging Clinical Activity In Second-Line EGFR Mutation-Positive Lung Cancer With MET-Amplification

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) and AstraZeneca PLC ("AstraZeneca") today presented preliminary safety and clinical activity data of savolitinib when given in combination with either...

Chi-Med Reports Preliminary Phase II Data On Fruquintinib Combination In First-Line Lung Cancer

Chi-Med Reports Preliminary Phase II Data On Fruquintinib Combination In First-Line Lung Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an investigational selective inhibitor of vascular endothelial...

Hutchison China MediTech: Appointment Of Director

Hutchison China MediTech: Appointment Of Director

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of the Technical Committee with effect from...

Chi-Med Highlights Oral Presentations At CSCO Annual Meeting

Chi-Med Highlights Oral Presentations At CSCO Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and theliatinib, were presented at the 20 th Annual...

Chi-Med To Present Savolitinib And Fruquintinib Clinical Data At WCLC 2017 Annual Meeting

Chi-Med To Present Savolitinib And Fruquintinib Clinical Data At WCLC 2017 Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that non-small cell lung cancer ("NSCLC") proof-of-concept clinical data on two of its novel tyrosine kinase inhibitors ("TKI"), savolitinib and...

Chi-Med Initiates A Phase I Clinical Trial Of Selective PI3Kd Inhibitor HMPL-689 In Lymphoma Patients In China

Chi-Med Initiates A Phase I Clinical Trial Of Selective PI3Kd Inhibitor HMPL-689 In Lymphoma Patients In China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL-689 in China.

Chi-Med Reports 2017 Interim Results And Updates Shareholders On Key Clinical Programs

Chi-Med Reports 2017 Interim Results And Updates Shareholders On Key Clinical Programs

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global...

Chi-Med Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL-453 in China.

Chi-Med Highlights Phase III Fruquintinib Data In Oral Presentation At ASCO

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) announced that results from its pivotal Phase III trial with fruquintinib, its novel vascular endothelial growth factor receptor ("VEGFR") kinase inhibitor, were...

Chi-Med Presents Clinical Data At ASCO 2017 Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that new clinical data on three of its novel tyrosine kinase inhibitors, fruquintinib, savolitinib and sulfatinib, will be presented at the 2017...

Chi-Med Presented Pre-clinical Data For Fruquintinib And Sulfatinib At The American Association For Cancer Research Annual Meeting 2017

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Cancer Research ("AACR") Annual Meeting 2017, held in Washington, D.

Presidents Trump and Xi Have 3 Major Issues to Discuss This Week

Presidents Trump and Xi Have 3 Major Issues to Discuss This Week

Currency manipulation, dumping and intellectual property are crucial themes for the meeting.

Chi-Med To Host R&D Briefings On March 29 & 30, 2017

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an overview of the Company's clinical...

Chi-Med: Grant Of Awards Under Long Term Incentive Plan

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards ("LTIP Awards") under the Long Term Incentive Plan ("LTIP") adopted by Chi-Med at its Annual...

Publication Of Annual Report And Financial Results For The Year Ended December 31, 2016

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announced today that on Monday March 13, 2017, it filed its annual report ("Annual Report") on Form 20-F with the U.

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results At The 14th Annual Conference Of European Neuroendocrine Tumor Society

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) presented data from the ongoing Phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine tumors ("NET") at the 14th Annual Conference...

Chi-Med Announces Positive Top-Line Results For FRESCO, Its Phase III Pivotal Registration Trial Of Fruquintinib In Patients With Locally Advanced Or Metastatic Colorectal Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic...

Chi Med Appoints Graeme Jack As Independent Non-executive Director And Chairman Of Audit Committee

Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- 1.

Chi-Med Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carcinoma ("PSC") in China.

Chi-Med And AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results At 2017 Genitourinary Cancers Symposium

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) and AstraZeneca PLC ("AstraZeneca") will present data from the ongoing Phase II clinical trial of savolitinib in patients with papillary renal cell carcinoma...

Chi-Med Initiates First-In-Human Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In Australia

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human ("FIH") Phase I clinical trial of HMPL-453 in Australia.